Co-Crystal Screening of Diclofenac
In the pharmaceutical industry, co-crystals are becoming increasingly valuable as crystalline solids that can offer altered/improved physical properties of an active pharmaceutical ingredient (API) without changing its chemical identity or biological activity. In order to identify new solid forms of...
Main Authors: | John Desper, Christer B. Aakeröy, Angela B. Grommet |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2011-08-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | http://www.mdpi.com/1999-4923/3/3/601/ |
Similar Items
-
The Impact of Halogen Substituents on the Synthesis and Structure of Co-Crystals of Pyridine Amides
by: Amila M. Abeysekera, et al.
Published: (2021-02-01) -
A systematic structural study of halogen bonding versus hydrogen bonding within competitive supramolecular systems
by: Christer B. Aakeröy, et al.
Published: (2015-09-01) -
Diclofenac-proline nano-co-crystal development, characterization, in vitro dissolution and diffusion study
by: Ilma Nugrahani, et al.
Published: (2020-09-01) -
2-Hydroxyethylammonium [2-(2,6-dichloroanilino)phenyl]acetate monohydrate
by: Nodira Obidova, et al.
Published: (2022-04-01) -
Structural Examination of Halogen-Bonded Co-Crystals of Tritopic Acceptors
by: Stefan N. L. Andree, et al.
Published: (2018-01-01)